Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2010 Oct;95(10):1621-3.
doi: 10.3324/haematol.2010.029231.

Generation of mature blood cells from pluripotent stem cells

Igor I Slukvin
Editorial

Generation of mature blood cells from pluripotent stem cells

Igor I Slukvin. Haematologica. 2010 Oct.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
The use of human induced pluripotent stem cells (PSC) and human embryonic stem cells for manufacturing blood products. Human PSC lines with the most commonly used RBC and platelet genotypes/phenotypes can be obtained and used for continuous manufacturing of blood products. To meet specific clinical needs (e.g., transfusion of alloimmunized patients, patients with rare blood groups), cells with unique genotypes/phenotypes can be obtained from a stem cell bank to manufacture blood products on demand. In addition, human PSC can be genetically modified to produce RBC for drug delivery or platelets for targeting specific pathways in the coagulation cascade to treat bleeding disorders or coagulopathies. Human PSC-derived hematopoietic progenitors can be used to treat bone marrow failure due to chemotherapy-induced myelotoxicity. Human PSC also provide an opportunity to manufacture dendritic cell-based vaccines for cancer immunotherapy with a broad variety of MHC genotypes/phenotypes. By using human PSC genetically engineered to express tumor-specific T-cell receptor, cytotoxic T cells can be produced to target malignant tumors.
See this image and copyright information in PMC

Comment on

References

    1. Mintz P, editor. Transfusion Therapy: Clinical Principles and Practice. 2nd ed. AABB Press; 2005.
    1. Douay L, Andreu G. Ex vivo production of human red blood cells from hematopoietic stem cells: what is the future in transfusion? Transfus Med Rev. 2007;21(2):91–100. - PubMed
    1. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7. - PubMed
    1. Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA. 2001;98(19):10716–21. - PMC - PubMed
    1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76. - PubMed